Cargando…

Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study

OBJECTIVES: We evaluated early medication persistence with new topical antiglaucoma eyedrops, omidenepag isopropyl 0.002% (a selective prostaglandin EP2 agonist). DESIGN AND SETTING: Retrospective two-institute study in Himeji and Akashi in Japan. PARTICIPANTS: We analysed patients with glaucoma who...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakakura, Shunsuke, Kanamori, Akiyasu, Fukuma, Yasuko, Wakabayashi, Seita, Nagata, Yuki, Adachi, Miku
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Ophthalmology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849894/ https://www.ncbi.nlm.nih.gov/pubmed/33514572 http://dx.doi.org/10.1136/bmjopen-2020-040301

Ejemplares similares

One-Year Follow-Up Study of Changes in Prostaglandin-Associated Periorbital Syndrome After Switch From Conventional Prostaglandin F2alfa to Omidenepag Isopropyl
por: Oogi, Satomi, et al.
Publicado: (2020)

Evaluation of Patterns and Correlations of the Degree of Conjunctival Hyperemia Induced by Omidenepag Isopropyl 0.002% and Ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Time course of conjunctival hyperemia induced by omidenepag isopropyl ophthalmic solution 0.002%: a pilot, comparative study versus ripasudil 0.4%
por: Terao, Etsuko, et al.
Publicado: (2020)

Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
por: Matsuo, Masato, et al.
Publicado: (2022)

Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2020)

Evaluation of New and Preexisting Epiretinal Membranes Following Glaucoma Filtration Surgery
por: Aoki, Ryota, et al.
Publicado: (2023)

Interim Results of Post-Marketing Observational Study of Omidenepag Isopropyl for Glaucoma and Ocular Hypertension in Japan
por: Nakazawa, Toru, et al.
Publicado: (2022)

A Case Report on Premature Twins: Primary Congenital Glaucoma or Large Cupping Disks Mimicking Primary Congenital Glaucoma?
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Effects of the Selective EP2 Receptor Agonist Omidenepag on Adipocyte Differentiation in 3T3-L1 Cells
por: Yamamoto, Yasuko, et al.
Publicado: (2020)

Evaluation of rebound tonometer iCare IC200 as compared with IcarePRO and Goldmann applanation tonometer in patients with glaucoma
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Twenty-Four-Hour Intraocular Pressure Control with Omidenepag Isopropyl 0.002% in Patients with Glaucoma and Ocular Hypertension
por: Shiratori, Naka, et al.
Publicado: (2021)

Effect of Prostaglandin E2 Agonist Omidenepag on the Expression of Matrix Metalloproteinase in Trabecular Meshwork Cells
por: Kim, Jeong Yeub, et al.
Publicado: (2022)

The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice
por: Esaki, Yoshihiko, et al.
Publicado: (2020)

Expression of prostaglandin E receptor subtype EP4 in conjunctival epithelium of patients with ocular surface disorders: case-control study
por: Ueta, Mayumi, et al.
Publicado: (2012)

Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study)
por: Aihara, Makoto, et al.
Publicado: (2019)

Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
por: Suzuki, Soma, et al.
Publicado: (2022)

Long-Term Follow-Up After Successful Trabeculectomy: A Case Report of Reversal of Cupping and Recovery of Visual Field Progression
por: Nakakura, Shunsuke, et al.
Publicado: (2021)

Insertion of Ahmed Implant With Partial Buckle Resection: A Case Report
por: Noguchi, Asuka, et al.
Publicado: (2022)

Torsional Power and Tip Shape Greatly Change Irrigation Flow Feeding Rate
por: Noguchi, Santaro, et al.
Publicado: (2023)

Anterior Segment Optical Coherence Tomography Analysis of Iris Morphometric Changes Induced by Prostaglandin Analogues Treatment in Patients with Primary Open Angle Glaucoma or Ocular Hypertension
por: Mancino, R, et al.
Publicado: (2018)

Omidenepag, a Selective, Prostanoid EP2 Agonist, Does Not Suppress Adipogenesis in 3D Organoids of Human Orbital Fibroblasts
por: Hikage, Fumihito, et al.
Publicado: (2021)

Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists
por: Chen, Jessica Y., et al.
Publicado: (2020)

Omidenepag Isopropyl in Latanoprost Low/Nonresponders With Primary Open Angle Glaucoma or Ocular Hypertension: A Phase 3, Nonrandomized, Two-Phase, Open-Label Study
por: Panarelli, Joseph F., et al.
Publicado: (2023)

Accuracy of a deep convolutional neural network in detection of retinitis pigmentosa on ultrawide-field images
por: Masumoto, Hiroki, et al.
Publicado: (2019)

Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm’s canal endothelial cells and ciliary muscle contraction
por: Nakamura, Natsuko, et al.
Publicado: (2021)

Effect of Ocular Dominance on Ocular Blood Flow Parameters
por: Nakaniida, Yuta, et al.
Publicado: (2023)

Efficacy and Safety of Omidenepag Isopropyl 0.002% Ophthalmic Solution: A Retrospective Analysis of Real-World Data in Japan
por: Miki, Atsuya, et al.
Publicado: (2022)

Cystoid macular edema associated with omidenepag isopropyl in a phakic eye with an implantable collamer lens: a case report
por: Bae, Byung-Jin, et al.
Publicado: (2023)

Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells
por: Ida, Yosuke, et al.
Publicado: (2020)

Conjunctivitis, Iritis, or Glaucoma?
Publicado: (1907)

Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications
por: Belamkar, Aditya, et al.
Publicado: (2022)

A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6)
por: Olander, Kenneth W., et al.
Publicado: (2021)

Clinical Audit on the Effectiveness of Clinic-Based Intraocular Pressure Phasing for Patients With Glaucoma and Glaucoma Suspect
por: Nanthini, Selvaraja, et al.
Publicado: (2022)

Association between topical beta-blockers and risks of cardiovascular and respiratory disease in patients with glaucoma: a retrospective cohort study
por: Chen, Hsin-Yi, et al.
Publicado: (2020)

Long-Term Outcomes of Ahmed Glaucoma Valve Surgery in a Scottish Cohort of Patients With Refractory Glaucoma
por: Siempis, Thomas, et al.
Publicado: (2023)

Reactivities of a Prostanoid EP2 Agonist, Omidenepag, Are Useful for Distinguishing between 3D Spheroids of Human Orbital Fibroblasts without or with Graves’ Orbitopathy
por: Ida, Yosuke, et al.
Publicado: (2021)

Confounder for Optic Disc Evaluation in Glaucoma
por: Thool, Archana R, et al.
Publicado: (2023)

Study profile: the Genetics of Glaucoma Study
por: Gharahkhani, Puya, et al.
Publicado: (2023)

Is glaucoma comprehension associated with psychological disturbance and vision-related quality of life for patients with glaucoma? A cross-sectional study
por: Kong, Xiang Mei, et al.
Publicado: (2014)

Epidemiology of Glaucoma: The Past, Present, and Predictions for the Future
por: Allison, Karen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qh2nb04559i57ipbgpf72tiei1